Advertisement

Drugs & Aging

, Volume 36, Issue 3, pp 189–202 | Cite as

Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease

  • Mark Dominic LattEmail author
  • Simon Lewis
  • Olfat Zekry
  • Victor S. C. Fung
Current Opinion

Abstract

Dopamine agonists (DAs) are frequently used in the management of Parkinson’s disease (PD), a complex multisystem disorder influenced substantially by age-related factors. Over 80% of PD patients present after age 60 years and may have clinical features exacerbated by age-related comorbidities or decline in physiological compensatory mechanisms. Pharmacotherapy for motor symptoms in older persons is more likely to involve exclusive use of levodopa combined with a peripheral decarboxylase inhibitor throughout the course of the illness. Non-ergot DAs, such as pramipexole, rotigotine and ropinirole, may be used as de novo monotherapy for the control of motor symptoms in older persons, although they are less efficacious than levodopa therapy. DAs may also be considered as adjunct therapy in older persons when motor symptoms are no longer adequately controlled by levodopa or when motor fluctuations and dyskinesia appear. DAs may be used cautiously in older persons with cognitive impairment and orthostatic hypotension but should be avoided when there is a history or risk of psychosis or impulse control disorders.

Notes

Compliance with Ethical Standards

Funding

No specific funding was received for this work by Mark Dominic Latt, Simon Lewis, Olfat Zekry or Victor S. C. Fung.

Conflict of interest

Mark Dominic Latt and Olfat Zekry report no conflicts of interest or additional disclosures. Simon Lewis reports honoraria from Stada and Teva. Victor S. C. Fung is a member of advisory boards for Abbvie, Allergan, Ipsen, Merz, Stada, Teva and UCB.

References

  1. 1.
    Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson’s disease. J Clin Epidemiol. 2002;55(1):25–31.Google Scholar
  2. 2.
    Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72(5):432–8.  https://doi.org/10.1212/01.wnl.0000341769.50075.bb.Google Scholar
  3. 3.
    Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003;60(4):529–33.Google Scholar
  4. 4.
    Santos Garcia D, Suarez Castro E, Exposito I, de Deus T, Tunas C, Aneiros A, et al. Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and control subjects. J Neurol Sci. 2017;373:210–5.  https://doi.org/10.1016/j.jns.2016.12.046.Google Scholar
  5. 5.
    Beydoun HA, Beydoun MA, Mishra NK, Rostant OS, Zonderman AB, Eid SM. Comorbid Parkinson’s disease, falls and fractures in the 2010 National Emergency Department sample. Parkinsonism Relat Disord. 2017;35:30–5.  https://doi.org/10.1016/j.parkreldis.2016.11.005.Google Scholar
  6. 6.
    Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780–91.  https://doi.org/10.1111/j.1532-5415.2007.01156.x.Google Scholar
  7. 7.
    Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson’s disease. J Neurol. 2001;248(11):950–8.Google Scholar
  8. 8.
    Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson’s disease. CNS Spectr. 2006;11(7):541–54.Google Scholar
  9. 9.
    Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.  https://doi.org/10.1002/mds.21956.Google Scholar
  10. 10.
    Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson’s disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–9.Google Scholar
  11. 11.
    Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson’s disease revisited—clinical features, natural history, and mortality. Mov Disord. 1998;13(6):885–94.  https://doi.org/10.1002/mds.870130605.Google Scholar
  12. 12.
    Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Young- versus older-onset Parkinson’s disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250–6.Google Scholar
  13. 13.
    Caslake R, Taylor K, Scott N, Harris C, Gordon J, Wilde K, et al. Age-, and gender-specific incidence of vascular parkinsonism, progressive supranuclear palsy, and parkinsonian-type multiple system atrophy in North East Scotland: the PINE study. Parkinsonism Relat Disord. 2014;20(8):834–9.  https://doi.org/10.1016/j.parkreldis.2014.04.013.Google Scholar
  14. 14.
    Olfson M, King M, Schoenbaum M. Antipsychotic treatment of adults in the United States. J Clin Psychiatry. 2015;76(10):1346–53.  https://doi.org/10.4088/JCP.15m09863.Google Scholar
  15. 15.
    Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59.  https://doi.org/10.2147/CIA.S13109.Google Scholar
  16. 16.
    Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord. 2001;16(3):507–10.Google Scholar
  17. 17.
    Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.Google Scholar
  18. 18.
    Sauerbier A, Jenner P, Todorova A, Chaudhuri KR. Non motor subtypes and Parkinson’s disease. Parkinsonism Relat Disord. 2016;22(Suppl 1):S41–6.  https://doi.org/10.1016/j.parkreldis.2015.09.027.Google Scholar
  19. 19.
    Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson’s disease. Neurology. 1988;38(12):1841–4.Google Scholar
  20. 20.
    Levy G. The relationship of Parkinson disease with aging. Arch Neurol. 2007;64(9):1242–6.  https://doi.org/10.1001/archneur.64.9.1242.Google Scholar
  21. 21.
    Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol. 2006;13(11):1170–85.  https://doi.org/10.1111/j.1468-1331.2006.01547.x.Google Scholar
  22. 22.
    PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial [erratum appears in Lancet. 2014 Sep 27;384(9949):1186]. Lancet. 2014;384(9949):1196–205.  https://doi.org/10.1016/S0140-6736(14)60683-8.Google Scholar
  23. 23.
    Lees A. Alternatives to levodopa in the initial treatment of early Parkinson’s disease. Drugs Aging. 2005;22(9):731–40.Google Scholar
  24. 24.
    Chen JJ, Fernandez HH. Community and long-term care management of Parkinson’s disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs Aging. 2007;24(8):663–80.Google Scholar
  25. 25.
    Mitchell SL, Sullivan EA, Lipsitz LA. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol. 1997;54(11):1393–8.Google Scholar
  26. 26.
    Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B. Treatment of patients with early and advanced Parkinson’s disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat Disord. 2013;19(1):37–42.  https://doi.org/10.1016/j.parkreldis.2012.06.009.Google Scholar
  27. 27.
    Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277(5692):93–6.Google Scholar
  28. 28.
    Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease. Neurology. 2002;58(4 Supplement (1)):S1–8.Google Scholar
  29. 29.
    Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183–9.  https://doi.org/10.1002/syn.21805.Google Scholar
  30. 30.
    Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–4.  https://doi.org/10.1136/jnnp-2013-306787.Google Scholar
  31. 31.
    Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84(4):310–6.  https://doi.org/10.1016/s0025-6196(11)60538-7.Google Scholar
  32. 32.
    Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, et al. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson’s disease. Intern Med. 2013;52(3):325–32.Google Scholar
  33. 33.
    Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791–804.Google Scholar
  34. 34.
    Borgemeester RW, Lees AJ, van Laar T. Parkinson’s disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat Disord. 2016;27:35–40.  https://doi.org/10.1016/j.parkreldis.2016.04.023.Google Scholar
  35. 35.
    Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002;303(2):805–14.Google Scholar
  36. 36.
    Borovac JA. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89(1):37–47.Google Scholar
  37. 37.
    Haro-Estarriol M, Sabater-Talaverano G, Rodriguez-Jerez F, Obrador-Lagares A, Genis-Batlle D, Sendra-Salillas S. Pleural effusion and pulmonary hypertension in a patient with Parkinson disease treated with cabergoline. Arch Bronconeumol. 2009;45(2):100–2.  https://doi.org/10.1016/j.arbres.2008.01.003.Google Scholar
  38. 38.
    Chaudhuri KR, Dhawan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord. 2004;19(12):1522–3.  https://doi.org/10.1002/mds.20330.Google Scholar
  39. 39.
    Townsend M, MacIver DH. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson’s disease. Heart. 2004;90(8):e47.  https://doi.org/10.1136/hrt.2004.036236.Google Scholar
  40. 40.
    Hely MA, Morris JG, Lawrence S, Jeremy R, Genge S. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy. Aust N Z J Med. 1991;21(1):82–4.Google Scholar
  41. 41.
    Hely MA, Morris JG, Reid WG, O’Sullivan DJ, Williamson PM, Rail D, et al. The Sydney multicentre study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994;57(8):903–10.Google Scholar
  42. 42.
    Renoux C, Dell’Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiol Drug Saf. 2012;21(1):34–41.  https://doi.org/10.1002/pds.2267.Google Scholar
  43. 43.
    Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39–46.Google Scholar
  44. 44.
    Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38.Google Scholar
  45. 45.
    Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology. 2003;61(6):859–61.Google Scholar
  46. 46.
    Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363(9416):1179–83.  https://doi.org/10.1016/s0140-6736(04)15945-x.Google Scholar
  47. 47.
    Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15(1):44–9.  https://doi.org/10.1007/s11102-011-0339-7.Google Scholar
  48. 48.
    Tan LC, Ng KK, Au WL, Lee RK, Chan YH, Tan NC. Bromocriptine use and the risk of valvular heart disease. Mov Disord. 2009;24(3):344–9.  https://doi.org/10.1002/mds.22228.Google Scholar
  49. 49.
    Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826–9.Google Scholar
  50. 50.
    Zadikoff C, Duong-Hua M, Sykora K, Marras C, Lang A, Rochon P. Pergolide associated cardiac valvulopathy based on Ontario administrative data. Can J Neurol Sci. 2008;35(2):173–8.Google Scholar
  51. 51.
    Tran T, Brophy JM, Suissa S, Renoux C. Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with Parkinson’s disease: a systematic review of observational studies. CNS Drugs. 2015;29(12):985–98.  https://doi.org/10.1007/s40263-015-0293-4.Google Scholar
  52. 52.
    Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res. 2012;65(3):358–64.  https://doi.org/10.1016/j.phrs.2011.11.009.Google Scholar
  53. 53.
    Hsieh PH, Hsiao FY. Risk of heart failure associated with dopamine agonists: a nested case–control study. Drugs Aging. 2013;30(9):739–45.  https://doi.org/10.1007/s40266-013-0102-z.Google Scholar
  54. 54.
    Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc. 1999;74(4):371–5.  https://doi.org/10.4065/74.4.371.Google Scholar
  55. 55.
    Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov Disord. 2009;24(1):129–33.  https://doi.org/10.1002/mds.22385.Google Scholar
  56. 56.
    McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med. 1988;148(10):2231–6.Google Scholar
  57. 57.
    Dewey RB 2nd, Reimold SC, O’Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol. 2007;64(3):377–80.Google Scholar
  58. 58.
    d’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37(47):3515–22.  https://doi.org/10.1093/eurheartj/ehw229.Google Scholar
  59. 59.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484–91.Google Scholar
  60. 60.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial [erratum appears in Arch Neurol. 2005 Mar;62(3):430]. Arch Neurol. 2004;61(7):1044–53.Google Scholar
  61. 61.
    Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–8.Google Scholar
  62. 62.
    Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology. 1998;51(4):1057–62.Google Scholar
  63. 63.
    Nomoto M, Iwaki H, Kondo H, Sakurai M. Efficacy and safety of rotigotine in elderly patients with Parkinson’s disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol. 2018;265(2):253–65.  https://doi.org/10.1007/s00415-017-8671-0.Google Scholar
  64. 64.
    Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2013;20(1):50–6.  https://doi.org/10.1111/j.1468-1331.2012.03712.x.Google Scholar
  65. 65.
    Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AHV, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–404.Google Scholar
  66. 66.
    Mizuno Y, Nomoto M, Kondo T, Hasegawa K, Murata M, Takeuchi M, et al. Transdermal rotigotine in early stage Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Mov Disord. 2013;28(10):1447–50.  https://doi.org/10.1002/mds.25537.Google Scholar
  67. 67.
    Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M, et al. Rotigotine vs ropinirole in advanced stage Parkinson’s disease: a double-blind study. Parkinsonism Relat Disord. 2014;20(12):1388–93.  https://doi.org/10.1016/j.parkreldis.2014.10.005.Google Scholar
  68. 68.
    Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295–310.  https://doi.org/10.2165/11318330-000000000-00000.Google Scholar
  69. 69.
    Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015;75(5):487–501.  https://doi.org/10.1007/s40265-015-0377-y.Google Scholar
  70. 70.
    Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy. 2009;29(12):1452–67.  https://doi.org/10.1592/phco.29.12.1452.Google Scholar
  71. 71.
    Mirapex ER® Full prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022421s003lbl.pdf. Accessed 8 July 2018.
  72. 72.
    Requip® Full prescibing information. GlaxoSmithKline, Research Triangle Park. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020658s024s026s027s030s032lbl.pdf. Accessed 8 July 2018.
  73. 73.
    Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39(4):243–54.  https://doi.org/10.2165/00003088-200039040-00001.Google Scholar
  74. 74.
    Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson’s disease. Mov Disord. 2000;15(4):664–8.Google Scholar
  75. 75.
    Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson’s disease. Expert Opin Investig Drugs. 2014;23(3):387–410.  https://doi.org/10.1517/13543784.2014.869209.Google Scholar
  76. 76.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 1998;55(Suppl 1):23–30.Google Scholar
  77. 77.
    Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2001;1:CD001518.  https://doi.org/10.1002/14651858.cd001518.Google Scholar
  78. 78.
    Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–83.  https://doi.org/10.1001/jama.2014.3654.Google Scholar
  79. 79.
    Reichmann H, Herting B, Miller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm. 2003;110(12):1393–400.Google Scholar
  80. 80.
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.Google Scholar
  81. 81.
    Parkinson’s Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three year interim report. BMJ. 1993;307(6902):469–72.Google Scholar
  82. 82.
    Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63(12):1756–60.  https://doi.org/10.1001/archneur.63.12.1756.Google Scholar
  83. 83.
    Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord. 1987;2(2):73–91.  https://doi.org/10.1002/mds.870020201.Google Scholar
  84. 84.
    Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov Disord. 2005;20(3):342–4.  https://doi.org/10.1002/mds.20360.Google Scholar
  85. 85.
    Ahlskog JE. Seniors with Parkinson’s disease: initial medical treatment. J Clin Neurol. 2010;6(4):159–66.  https://doi.org/10.3988/jcn.2010.6.4.159.Google Scholar
  86. 86.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol. 2006;63(2):205–9.  https://doi.org/10.1001/archneur.63.2.205.Google Scholar
  87. 87.
    Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, Parkinson Study Group T, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66(9):1427–9.Google Scholar
  88. 88.
    Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–66.  https://doi.org/10.1002/mds.27372.Google Scholar
  89. 89.
    Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, et al. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and l-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012;35(4):174–81.  https://doi.org/10.1097/WNF.0b013e31825f77b9.Google Scholar
  90. 90.
    Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 2013;19(11):1022–6.  https://doi.org/10.1016/j.parkreldis.2013.07.009.Google Scholar
  91. 91.
    Ossig C, Reichmann H. Treatment of Parkinson’s disease in the advanced stage. J Neural Transm. 2013;120(4):523–9.  https://doi.org/10.1007/s00702-013-1008-y.Google Scholar
  92. 92.
    Stowe R, Ives N, Clarke CE, Deane K, Wheatley K, Gray R, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010;7:CD007166.  https://doi.org/10.1002/14651858.cd007166.pub2.Google Scholar
  93. 93.
    MacMahon DG. The initial drug treatment of older patients with Parkinson’s disease—consider an agonist, but don’t demonise dopa. Age Ageing. 2003;32(3):244–5.Google Scholar
  94. 94.
    Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson’s disease: an evidence-based comparison. Drugs Aging. 2003;20(11):847–55.Google Scholar
  95. 95.
    Hietanen M, Teravainen H. The effect of age of disease onset on neuropsychological performance in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(2):244–9.Google Scholar
  96. 96.
    Fasano A, Guidubaldi A, De Nigris F, Bentivoglio AR. Safety and efficacy of rotigotine in individuals with Parkinson’s disease aged 75 and older. J Am Geriatr Soc. 2011;59(12):2386–7.  https://doi.org/10.1111/j.1532-5415.2011.03689.x.Google Scholar
  97. 97.
    Woitalla D, Kassubek J, Timmermann L, Lauterbach T, Berkels R, Grieger F, et al. Reduction of gastrointestinal symptoms in Parkinson’s disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord. 2015;21(3):199–204.  https://doi.org/10.1016/j.parkreldis.2014.11.024.Google Scholar
  98. 98.
    Ritter JM. Cardiac safety, drug-induced QT prolongation and torsade de pointes (TdP). Br J Clin Pharmacol. 2012;73(3):331–4.  https://doi.org/10.1111/j.1365-2125.2012.04193.x.Google Scholar
  99. 99.
    Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37. https://doi.org/10.1038/ajg.2012.373.Google Scholar
  100. 100.
    Umehara T, Toyoda C, Oka H. Postprandial hypotension in de novo Parkinson’s disease: a comparison with orthostatic hypotension. Parkinsonism Relat Disord. 2014;20(6):573–7.  https://doi.org/10.1016/j.parkreldis.2014.02.007.Google Scholar
  101. 101.
    Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, et al. Orthostatic hypotension in de novo Parkinson disease. Arch Neurol. 2003;60(10):1400–4.  https://doi.org/10.1001/archneur.60.10.1400.Google Scholar
  102. 102.
    Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension. 1992;19(6 Pt 1):508–19.Google Scholar
  103. 103.
    Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson’s disease. Arch Neurol. 2000;57(10):1461–3.Google Scholar
  104. 104.
    Mehagnoul-Schipper DJ, Boerman RH, Hoefnagels WH, Jansen RW. Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients. J Gerontol A Biol Sci Med Sci. 2001;56(12):M749–55.Google Scholar
  105. 105.
    Lang AE. Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy. Arch Neurol. 2001;58(5):835.Google Scholar
  106. 106.
    Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–9.Google Scholar
  107. 107.
    Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, et al. Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf. 2014;13(3):351–60.  https://doi.org/10.1517/14740338.2014.888057.Google Scholar
  108. 108.
    Investigators PSGCC. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-70.Google Scholar
  109. 109.
    Biglan KM, Holloway RG Jr, McDermott MP, Richard IH, Parkinson Study Group C-PDI. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69(2):187–95.Google Scholar
  110. 110.
    Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson’s disease. Clin Neuropharmacol. 1998;21(3):169–75.Google Scholar
  111. 111.
    Ceravolo R, Rossi C, Del Prete E, Bonuccelli U. A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2016;15(2):181–98.  https://doi.org/10.1517/14740338.2016.1130128.Google Scholar
  112. 112.
    Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol. 2004;61(1):97–102.  https://doi.org/10.1001/archneur.61.1.97.Google Scholar
  113. 113.
    Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52(9):1908–10.Google Scholar
  114. 114.
    Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9.  https://doi.org/10.1002/mds.23441.Google Scholar
  115. 115.
    Garcia Ruiz PJ. Sleep attack associated to rotigotine. Clin Neuropharmacol. 2009;32(6):365.  https://doi.org/10.1097/WNF.0b013e3181a946d5.Google Scholar
  116. 116.
    Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, et al. Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson’s disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol. 2006;13(3):209–14.  https://doi.org/10.1111/j.1468-1331.2006.01262.x.Google Scholar
  117. 117.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733–46.Google Scholar
  118. 118.
    Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord. 2000;15(2):201–11.Google Scholar
  119. 119.
    Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–7.  https://doi.org/10.1056/nejm199307153290303.Google Scholar
  120. 120.
    Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract. 2014;20(3):196–206.  https://doi.org/10.1097/01.pra.0000450319.21859.6d.Google Scholar
  121. 121.
    Warren N, O’Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017;88(12):1060–4.  https://doi.org/10.1136/jnnp-2017-315985.Google Scholar
  122. 122.
    Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41(1):19–75.  https://doi.org/10.1007/s40264-017-0590-6.Google Scholar
  123. 123.
    Carriere N, Kreisler A, Dujardin K, Destee A, Defebvre L. Impulse control disorders in Parkinson’s disease: a cohort of 35 patients. Rev Neurol (Paris). 2012;168(2):143–51.  https://doi.org/10.1016/j.neurol.2011.07.010.Google Scholar
  124. 124.
    Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord. 2013;28(3):327–33.  https://doi.org/10.1002/mds.25291.Google Scholar
  125. 125.
    Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261–5.  https://doi.org/10.1097/WNF.0b013e31826e6e6d.Google Scholar
  126. 126.
    Sohtaoglu M, Demiray DY, Kenangil G, Ozekmekci S, Erginoz E. Long term follow-up of Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16(5):334–7.  https://doi.org/10.1016/j.parkreldis.2010.02.006.Google Scholar
  127. 127.
    Todorova A, Samuel M, Brown RG, Chaudhuri KR. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years’ follow-up. Clin Neuropharmacol. 2015;38(4):132–4.  https://doi.org/10.1097/wnf.0000000000000091.Google Scholar
  128. 128.
    Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–6.  https://doi.org/10.1002/mds.26067.Google Scholar
  129. 129.
    Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58–63.  https://doi.org/10.1001/archneurol.2009.294.Google Scholar
  130. 130.
    Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(9):1051–2.  https://doi.org/10.1016/j.parkreldis.2012.05.012.Google Scholar
  131. 131.
    Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson’s disease. Mov Disord. 2000;15(5):789–94.Google Scholar
  132. 132.
    Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa–carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.  https://doi.org/10.1016/s1474-4422(13)70293-x.Google Scholar
  133. 133.
    Buongiorno M, Antonelli F, Camara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord. 2015;21(8):871–6.  https://doi.org/10.1016/j.parkreldis.2015.05.014.Google Scholar
  134. 134.
    Titova N, Chaudhuri KR. Apomorphine therapy in Parkinson’s and future directions. Parkinsonism Relat Disord. 2016;33(Suppl 1):S56–60.  https://doi.org/10.1016/j.parkreldis.2016.11.013.Google Scholar
  135. 135.
    Sesar A, Fernandez-Pajarin G, Ares B, Rivas MT, Castro A. Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients. J Neurol. 2017;264(5):946–54.  https://doi.org/10.1007/s00415-017-8477-0.Google Scholar
  136. 136.
    Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, et al. Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations. Brain. 2001;124(Pt 2):331–40.Google Scholar
  137. 137.
    Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000;15(4):613–26.Google Scholar
  138. 138.
    Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease. Mov Disord Clin Pract. 2017;4(1):78–83.  https://doi.org/10.1002/mdc3.12350.Google Scholar
  139. 139.
    Boyle A, Ondo W. Role of apomorphine in the treatment of Parkinson’s disease. CNS Drugs. 2015;29(2):83–9.  https://doi.org/10.1007/s40263-014-0221-z.Google Scholar
  140. 140.
    Kimber TE, Fang J, Huddy LJ, Thompson PD. Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study. Intern Med J. 2017;47(5):570–3.  https://doi.org/10.1111/imj.13378.Google Scholar
  141. 141.
    Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord. 2002;17(1):188–91.  https://doi.org/10.1002/mds.1276.Google Scholar
  142. 142.
    Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749–59.  https://doi.org/10.1016/s1474-4422(18)30239-4.Google Scholar
  143. 143.
    Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years. Arch Gerontol Geriatr Suppl. 2004;9:291–6.  https://doi.org/10.1016/j.archger.2004.04.039.Google Scholar
  144. 144.
    Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, et al. Integrated safety of levodopa–carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016;31(4):538–46.  https://doi.org/10.1002/mds.26485.Google Scholar
  145. 145.
    Udd M, Lyytinen J, Eerola-Rautio J, Kenttämies A, Lindström O, Kylänpää L, et al. Problems related to levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease. Brain Behav. 2017;7(7):e00737.  https://doi.org/10.1002/brb3.737.Google Scholar
  146. 146.
    Antonini A, Fung VSC, Boyd JT, Slevin JT, Hall C, Chatamra K, et al. Effect of levodopa–carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord. 2016;31(4):530–7.  https://doi.org/10.1002/mds.26528.Google Scholar
  147. 147.
    DeLong MR, Huang KT, Gallis J, Lokhnygina Y, Parente B, Hickey P, et al. Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. JAMA Neurol. 2014;71(10):1290–5.  https://doi.org/10.1001/jamaneurol.2014.1272.Google Scholar
  148. 148.
    Rughani AI, Hodaie M, Lozano AM. Acute complications of movement disorders surgery: effects of age and comorbidities. Mov Disord. 2013;28(12):1661–7.  https://doi.org/10.1002/mds.25610.Google Scholar
  149. 149.
    de Souza R-M, Moro E, Lang AE, Schapira AH. Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol. 2013;73(5):565–75.  https://doi.org/10.1002/ana.23890.Google Scholar
  150. 150.
    Aquino CC, Lozano AM, Lang AE. Deep brain stimulation for Parkinson disease in elderly individuals. JAMA Neurol. 2015;72(3):367.  https://doi.org/10.1001/jamaneurol.2014.4216.Google Scholar
  151. 151.
    Russmann H, Ghika J, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR, et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology. 2004;63(10):1952–4.Google Scholar
  152. 152.
    Derost PP, Ouchchane L, Morand D, Ulla M, Llorca PM, Barget M, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology. 2007;68(17):1345–55.  https://doi.org/10.1212/01.wnl.0000260059.77107.c2.Google Scholar
  153. 153.
    Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28(8):1065–78.  https://doi.org/10.1016/j.clinthera.2006.08.004.Google Scholar
  154. 154.
    Agundez JA, Garcia-Martin E, Alonso-Navarro H, Jimenez-Jimenez FJ. Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 2013;9(7):859–74.  https://doi.org/10.1517/17425255.2013.789018.Google Scholar
  155. 155.
    Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143(3):371–8.Google Scholar
  156. 156.
    Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937–43.Google Scholar
  157. 157.
    Castro Caldas A, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson’s disease: negatives versus positives. Expert Opin Drug Saf. 2018;17(3):331–7.  https://doi.org/10.1080/14740338.2018.1433659.Google Scholar
  158. 158.
    Cruse B, Morales-Briceño H, Chang FCF, Mahant N, Ha AD, Kim SD, et al. 24-hour levodopa–carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease. NPJ Parkinson’s Dis. 2018;4(1):34.  https://doi.org/10.1038/s41531-018-0070-4.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mark Dominic Latt
    • 1
    Email author
  • Simon Lewis
    • 2
  • Olfat Zekry
    • 3
  • Victor S. C. Fung
    • 4
  1. 1.Geriatric Medicine DepartmentUniversity of Sydney, Royal Prince Alfred HospitalCamperdownAustralia
  2. 2.Parkinson’s Disease Research Clinic, Brain and Mind CentreUniversity of SydneySydneyAustralia
  3. 3.Department of Pharmacy, Royal Prince Alfred HospitalUniversity of SydneySydneyAustralia
  4. 4.Department of Neurology, Westmead HospitalUniversity of SydneySydneyAustralia

Personalised recommendations